Neurology: Volume 100, Number 5, January 31, 2023 Exam #1 - Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort

About this course

  • Released: 01/31/2023
  • Expires: 01/31/2026

 

VALIDITY AND PERFORMANCE OF BLOOD BIOMARKERS FOR ALZHEIMER DISEASE TO PREDICT DEMENTIA RISK IN A LARGE CLINIC-BASED COHORT


LEARNING OBJECTIVES:

Upon completion of the article by Planche et al, the participant should be able to:

  • State how certain blood biomarkers were able to identify patients with amyloid-PET positivity (based on results of ROC analyses) in this study
  • Describe how blood biomarkers alone, a clinical prediction model (utilizing age, sex, education, memory, and executive performance) alone, and these approaches together performed in predicting the future risk of Alzheimer disease (AD) in this study
  • Discuss how the addition of certain medical comorbidities (chronic kidney disease, cardiovascular disease) impacted the ability of blood biomarkers and a clinical prediction model to predict the future risk of AD in this study

CORE COMPETENCIES:

The article by Planche et al covers the following core competency:
  • Medical knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures. All relevant financial relationships have been mitigated.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME